<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZEBETA- bisoprolol fumarate tablet </strong><br>Duramed Pharmaceuticals, Inc.<br></p></div>
<h1>ZEBETA<span class="Sup">®  </span><br>(Bisoprolol Fumarate) Tablets</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_05ae34db-16ba-40ec-bcfe-9336eaf5c6c9"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">November 2010</span><br><span class="Bold">799-33-100004</span><br><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_a7200693-fccc-47c1-b4a6-64875f958fb5"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">ZEBETA (bisoprolol fumarate) is a synthetic, beta<span class="Sub">1</span>-selective (cardioselective) adrenoceptor blocking agent. The chemical name for bisoprolol fumarate is (±)-1-[4-[[2-(1-Methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]-2-propanol(<span class="Italics">E</span>)-2-butenedioate (2:1) (salt). It possesses an asymmetric carbon atom in its structure and is provided as a racemic mixture. The S(-) enantiomer is responsible for most of the beta-blocking activity. Its empirical formula is (C<span class="Sub">18</span>H<span class="Sub">31</span>NO<span class="Sub">4</span>)<span class="Sub">2</span>•C<span class="Sub">4</span>H<span class="Sub">4</span>O<span class="Sub">4</span> and its structure is:</p>
<div class="Figure"><img alt="Bisoprolol Fumarate Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a11548a0-9c0f-4729-907c-75d8f99a6c85&amp;name=dffa820b-820f-4f21-a679-e7bdb047d0bc-01.jpg"></div>
<p>Bisoprolol fumarate has a molecular weight of 766.97. It is a white crystalline powder which is approximately equally hydrophilic and lipophilic, and is readily soluble in water, methanol, ethanol, and chloroform.</p>
<p>ZEBETA is available as 5 and 10 mg tablets for oral administration.</p>
<p>Inactive ingredients include Colloidal Silicon Dioxide, Corn Starch, Crospovidone, Dibasic Calcium Phosphate, Hypromellose, Magnesium Stearate, Microcrystalline Cellulose, Polyethylene Glycol, Polysorbate 80, and Titanium Dioxide. The 5 mg tablets also contain Red and Yellow Iron Oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_70b33391-76c3-43f4-be91-df3e9562a014"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">ZEBETA is a beta<span class="Sub">1</span>-selective (cardioselective) adrenoceptor blocking agent without significant membrane stabilizing activity or intrinsic sympathomimetic activity in its therapeutic dosage range. Cardioselectivity is not absolute, however, and at higher doses (<span class="Underline">&gt;</span> 20mg) bisoprolol fumarate also inhibits beta<span class="Sub">2</span>-adrenoceptors, chiefly located in the bronchial and vascular musculature; to retain selectivity it is therefore important to use the lowest effective dose.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f19ee431-53d1-4530-b25b-e0970a4f2e70"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics and Metabolism</h2>
<p class="First">The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%. Absorption is not affected by the presence of food. The first pass metabolism of bisoprolol fumarate is about 20%.</p>
<p>Binding to serum proteins is approximately 30%. Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg. Once daily dosing with bisoprolol fumarate results in less than twofold intersubject variation in peak plasma levels. The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population. Steady state is attained within 5 days of once daily dosing. In both young and elderly populations, plasma accumulation is low; the accumulation factor ranges from 1.1 to 1.3, and is what would be expected from the first order kinetics and once daily dosing. Plasma concentrations are proportional to the administered dose in the range of 5 to 20 mg. Pharmacokinetic characteristics of the two enantiomers are similar.</p>
<p>Bisoprolol fumarate is eliminated equally by renal and non-renal pathways with about 50% of the dose appearing unchanged in the urine and the remainder appearing in the form of inactive metabolites. In humans, the known metabolites are labile or have no known pharmacologic activity. Less than 2% of the dose is excreted in the feces. Bisoprolol fumarate is not metabolized by cytochrome P450 II D6 (debrisoquin hydroxylase).</p>
<p>In subjects with creatinine clearance less than 40 mL/min, the plasma half-life is increased approximately threefold compared to healthy subjects.</p>
<p>In patients with cirrhosis of the liver, the elimination of ZEBETA (bisoprolol fumarate) is more variable in rate and significantly slower than that in healthy subjects, with plasma half-life ranging from 8.3 to 21.7 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7d4fc550-3489-45ee-959a-07a2c89905c7"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">The most prominent effect of ZEBETA is the negative chronotropic effect, resulting in a reduction in resting and exercise heart rate. There is a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in resting and exercise <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> with little observed change in <span class="product-label-link" type="condition" conceptid="4231869" conceptname="Stroke volume">stroke volume</span>, and only a small increase in right atrial pressure, or pulmonary capillary wedge pressure at rest or during exercise.</p>
<p>Findings in short-term clinical hemodynamics studies with ZEBETA are similar to those observed with other beta-blocking agents.</p>
<p>The mechanism of action of its antihypertensive effects has not been completely established. Factors which may be involved include:</p>
<ol>
<li>Decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>,</li>
<li>Inhibition of renin release by the kidneys,</li>
<li>Diminution of tonic sympathetic outflow from the vasomotor centers in the brain.</li>
</ol>
<p>In normal volunteers, ZEBETA therapy resulted in a reduction of exercise- and isoproterenol-induced <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. The maximal effect occurred within 1-4 hours post-dosing. Effects persisted for 24 hours at doses equal to or greater than 5 mg.</p>
<p>Electrophysiology studies in man have demonstrated that ZEBETA significantly decreases heart rate, increases sinus node recovery time, prolongs AV node refractory periods, and, with rapid atrial stimulation, prolongs AV nodal conduction.</p>
<p>Beta<span class="Sub">1</span>-selectivity of ZEBETA has been demonstrated in both animal and human studies. No effects at therapeutic doses on beta<span class="Sub">2</span>-adrenoceptor density have been observed. Pulmonary function studies have been conducted in healthy volunteers, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatics</span>, and patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>). Doses of ZEBETA ranged from 5 to 60 mg, atenolol from 50 to 200 mg, metoprolol from 100 to 200 mg, and propranolol from 40 to 80 mg. In some studies, slight, asymptomatic increases in airways resistance (AWR) and decreases in forced expiratory volume (FEV<span class="Sub">1</span>) were observed with doses of bisoprolol fumarate 20 mg and higher, similar to the small increases in AWR also noted with the other cardioselective beta-blockers. The changes induced by beta-blockade with all agents were reversed by bronchodilator therapy.</p>
<p>ZEBETA had minimal effect on serum lipids during antihypertensive studies. In U.S. placebo-controlled trials, changes in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> averaged +0.8% for bisoprolol fumarate-treated patients, and +0.7% for placebo. Changes in triglycerides averaged +19% for bisoprolol fumarate-treated patients, and +17% for placebo.</p>
<p>ZEBETA (bisoprolol fumarate) has also been given concomitantly with thiazide diuretics. Even very low doses of hydrochlorothiazide (6.25 mg) were found to be additive with bisoprolol fumarate in lowering blood pressure in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_d2bb1815-850a-4b15-9816-6a2441ac65b4"></a><a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">In two randomized double-blind placebo-controlled trials conducted in the U.S., reductions in systolic and diastolic blood pressure and heart rate 24 hours after dosing in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> are shown below. In both studies, mean systolic/diastolic blood pressures at baseline were approximately 150/100 mm Hg, and mean heart rate was 76 bpm. Drug effect is calculated by subtracting the placebo effect from the overall change in blood pressure and heart rate.</p>
<a name="id_fe8ba8e8-51c6-4f2d-8ac5-20339a22c955"></a><table width="554">
<caption><span>Sitting Systolic/Diastolic Pressure (BP) and Heart Rate (HR) Mean Decrease (Δ) After 3 to 4 Weeks</span></caption>
<col width="30.7%">
<col width="16.8%">
<col width="13.9%">
<col width="22.7%">
<col width="15.9%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Observed total change from baseline minus placebo.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top"><span class="Bold"><span class="Underline">Study A</span></span></td>
<td class="Toprule" align="center" valign="top"></td>
<td class="Toprule" align="left" colspan="2" valign="top"><span class="Underline"><span class="Bold">Bisoprolol Fumarate</span></span></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">Placebo</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">5 mg</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">10 mg</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">20 mg</span></span></td>
</tr>
<tr>
<td align="left" valign="top">n=</td>
<td align="left" valign="top">61</td>
<td align="left" valign="top">61</td>
<td align="left" valign="top">61</td>
<td align="left" valign="top">61</td>
</tr>
<tr>
<td align="left" valign="top">Total ΔBP (mm Hg)</td>
<td align="left" valign="top">5.4/3.2</td>
<td align="left" valign="top">10.4/8.0</td>
<td align="left" valign="top">11.2/10.9</td>
<td align="left" valign="top">12.8/11.9</td>
</tr>
<tr>
<td align="left" valign="top">Drug Effect<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> </td>
<td align="left" valign="top">-</td>
<td align="left" valign="top">5.0/4.8</td>
<td align="left" valign="top">5.8/7.7</td>
<td align="left" valign="top">7.4/8.7</td>
</tr>
<tr>
<td align="left" valign="top">Total ΔHR (bpm)</td>
<td align="left" valign="top">0.5</td>
<td align="left" valign="top">7.2</td>
<td align="left" valign="top">8.7</td>
<td align="left" valign="top">11.3</td>
</tr>
<tr>
<td align="left" valign="top">Drug Effect<a href="#footnote-1" class="Sup">*</a>
</td>
<td align="left" valign="top">-</td>
<td align="left" valign="top">6.7</td>
<td align="left" valign="top">8.2</td>
<td align="left" valign="top">10.8</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold"><span class="Underline">Study B</span></span></td>
<td align="left" valign="top"></td>
<td align="left" colspan="2" valign="top"><span class="Bold"><span class="Underline">Bisoprolol Fumarate</span></span></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">Placebo</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">2.5 mg</span></span></td>
<td align="left" valign="top"><span class="Bold"><span class="Underline">10 mg</span></span></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">n=</td>
<td align="left" valign="top">56</td>
<td align="left" valign="top">59</td>
<td align="left" valign="top">62</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Total ΔBP (mm Hg)</td>
<td align="left" valign="top">3.0/3.7</td>
<td align="left" valign="top">7.6/8.1</td>
<td align="left" valign="top">13.5/11.2</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Drug Effect<a href="#footnote-1" class="Sup">*</a>
</td>
<td align="left" valign="top">-</td>
<td align="left" valign="top">4.6/4.4</td>
<td align="left" valign="top">10.5/7.5</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Total ΔHR (bpm)</td>
<td align="left" valign="top">1.6</td>
<td align="left" valign="top">3.8</td>
<td align="left" valign="top">10.7</td>
<td align="left" valign="top"></td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">Drug Effect<a href="#footnote-1" class="Sup">*</a>
</td>
<td align="left" valign="top">-</td>
<td align="left" valign="top">2.2</td>
<td align="left" valign="top">9.1</td>
<td align="left" valign="top"></td>
</tr>
</tbody>
</table>
<p>Blood pressure responses were seen within one week of treatment and changed little thereafter. They were sustained for 12 weeks and for over a year in studies of longer duration. Blood pressure returned to baseline when bisoprolol fumarate was tapered over two weeks in a long-term study.</p>
<p>Overall, significantly greater blood pressure reductions were observed on bisoprolol fumarate than on placebo regardless of race, age, or gender. There were no significant differences in response between black and nonblack patients.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_0ed48147-5804-43d7-9f8b-7ec389152027"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">ZEBETA is indicated in the management of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. It may be used alone or in combination with other antihypertensive agents.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_172e6ec0-df76-4d63-b91f-fbd42ae6fa01"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">ZEBETA is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>, overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, second or <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">third degree AV block</span>, and marked <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_2f7fb7b9-d290-40ee-950f-875d22708cec"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0b7ace89-3186-4de7-8a81-9508aefba31f"></a><a name="section-7.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h2>
<p class="First">Sympathetic stimulation is a vital component supporting circulatory function in the setting of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, and beta-blockade may result in further <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of myocardial contractility and precipitate more severe failure. In general, beta-blocking agents should be avoided in patients with overt congestive failure. However, in some patients with compensated <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> it may be necessary to utilize them. In such a situation, they must be used cautiously.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_946eb847-fa08-413a-8425-399d072195c5"></a><a name="section-7.2"></a><p></p>
<h2>In Patients Without a History of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h2>
<p class="First">Continued <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the myocardium with beta-blockers can, in some patients, precipitate <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. At the first signs or symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, discontinuation of ZEBETA should be considered. In some cases, beta-blocker therapy can be continued while <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is treated with other drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_12cf7dbd-dff1-4cf1-b926-619ddd32a4df"></a><a name="section-7.3"></a><p></p>
<h2>Abrupt Cessation of Therapy</h2>
<p class="First">Exacerbation of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, and, in some instances, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>, have been observed in patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> following abrupt cessation of therapy with beta-blockers. Such patients should, therefore, be cautioned against interruption or discontinuation of therapy without the physician’s advice. Even in patients without overt <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, it may be advisable to taper therapy with ZEBETA over approximately one week with the patient under careful observation. If withdrawal symptoms occur, ZEBETA therapy should be reinstituted, at least temporarily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c1aa8fa3-8496-437c-844c-d4aeefc7d607"></a><a name="section-7.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral Vascular Disease</span></h2>
<p class="First">Beta-blockers can precipitate or aggravate symptoms of <span class="product-label-link" type="condition" conceptid="4109870" conceptname="Arterial insufficiency">arterial insufficiency</span> in patients with <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>. Caution should be exercised in such individuals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_97ea2894-d598-49b4-8bc8-12697c1b4943"></a><a name="section-7.5"></a><p></p>
<h2>Bronchospastic Disease</h2>
<p class="First"><span class="Bold">PATIENTS WITH BRONCHOSPASTIC DISEASE SHOULD, IN GENERAL, NOT RECEIVE BETA-BLOCKERS. Because of its relative beta<span class="Sub">1</span>-selectivity, however, ZEBETA may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. Since beta<span class="Sub">1</span>-selectivity is not absolute, the lowest possible dose of ZEBETA should be used, with therapy starting at 2.5 mg. A beta<span class="Sub">2</span> agonist (bronchodilator) should be made available</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_87e07ab2-81e9-4d9f-adce-57b66747cb70"></a><a name="section-7.6"></a><p></p>
<h2>Major Surgery</h2>
<p class="First">Chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery; however, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fd2dd1bf-4df3-4f11-a34e-b9536b291501"></a><a name="section-7.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<p class="First">Beta-blockers may mask some of the manifestations of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, particularly <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. Nonselective beta-blockers may potentiate insulin-induced <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and delay recovery of serum glucose levels. Because of its beta<span class="Sub">1</span>-selectivity, this is less likely with ZEBETA. However, patients subject to spontaneous <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_abacaeab-d722-4338-be32-ce0066d5f955"></a><a name="section-7.8"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span></h2>
<p class="First">Beta-adrenergic blockade may mask clinical signs of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, such as <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. Abrupt withdrawal of beta-blockade may be followed by an exacerbation of the symptoms of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> or may precipitate <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_2a6aea21-a851-4236-9972-f79abf764154"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c7a87ac8-bc28-411e-9219-9287f1093775"></a><a name="section-8.1"></a><p></p>
<h2>Impaired Renal or Hepatic Function</h2>
<p class="First">Use caution in adjusting the dose of ZEBETA in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (see <a href="#i4i_clinical_pharmacology_id_70b33391-76c3-43f4-be91-df3e9562a014">CLINICAL PHARMACOLOGY</a> and <a href="#i4i_dosage_admin_id_9795357f-6a11-45ed-b13a-ed2146385812">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_3a2d0498-5b02-43f9-a950-bfa7c118e849"></a><a name="section-8.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">ZEBETA should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.</p>
<p>ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.</p>
<p>Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.</p>
<p>Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA. However, initial dose modification is generally not necessary. Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics, and cimetidine. There was no effect of ZEBETA on <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients on stable doses of warfarin.</p>
<p><span class="Italics">Risk of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reaction</span>: <br></span>While taking beta-blockers, patients with a history of severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_ee4cb6de-0585-492a-869b-7c46029e95a5"></a><a name="section-8.3"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients, especially those with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, should be warned about discontinuing use of ZEBETA without a physician’s supervision. Patients should also be advised to consult a physician if any difficulty in breathing occurs, or if they develop signs or symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> or excessive <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.</p>
<p>Patients subject to spontaneous <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned that beta-blockers may mask some of the manifestations of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, particularly <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and bisoprolol fumarate should be used with caution.</p>
<p>Patients should know how they react to this medicine before they operate automobiles and machinery or engage in other tasks requiring alertness.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_59846e45-188b-4da6-a651-c550dca24bf3"></a><a name="section-8.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies were conducted with oral bisoprolol fumarate administered in the feed of mice (20 and 24 months) and rats (26 months). No evidence of carcinogenic potential was seen in mice dosed up to 250 mg/kg/day or rats dosed up to 125 mg/kg/day. On a body weight basis, these doses are 625 and 312 times, respectively, the maximum recommended human dose (MRHD) of 20 mg, (or 0.4 mg/kg/day based on a 50 kg individual); on a body surface area basis, these doses are 59 times (mice) and 64 times (rats) the MRHD. The mutagenic potential of bisoprolol fumarate was evaluated in the microbial mutagenicity (Ames) test, the point mutation and chromosome aberration assays in Chinese hamster V79 cells, the unscheduled DNA synthesis test, the micronucleus test in mice, and the cytogenetics assay in rats. There was no evidence of mutagenic potential in these <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> assays.</p>
<p>Reproduction studies in rats did not show any impairment of fertility at doses up to 150 mg/kg/day of bisoprolol fumarate, or 375 and 77 times the MRHD on the basis of body weight and body surface area, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_35e573db-c6df-4e9c-a575-c9896dacb53e"></a><a name="section-8.5"></a><p></p>
<h2>Pregnancy Category C</h2>
<p class="First">In rats, bisoprolol fumarate was not teratogenic at doses up to 150 mg/kg/day which is 375 and 77 times the MRHD on the basis of body weight and body surface area, respectively. Bisoprolol fumarate was fetotoxic (increased late resorptions) at 50 mg/kg/day and maternotoxic (decreased food intake and body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>) at 150 mg/kg/day. The fetotoxicity in rats occurred at 125 times the MRHD on a body weight basis and 26 times the MRHD on the basis of body surface area. The maternotoxicity occurred at 375 times the MRHD on a body weight basis and 77 times the MRHD on the basis of body surface area. In rabbits, bisoprolol fumarate was not teratogenic at doses up to 12.5 mg/kg/day, which is 31 and 12 times the MRHD based on body weight and body surface area, respectively, but was embryolethal (increased early resorptions) at 12.5 mg/kg/day.</p>
<p>There are no adequate and well-controlled studies in pregnant women. ZEBETA (bisoprolol fumarate) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_d270b3b1-a984-4ed9-8f5c-21c4d854403c"></a><a name="section-8.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Small amounts of bisoprolol fumarate (&lt; 2% of the dose) have been detected in the milk of lactating rats. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk caution should be exercised when bisoprolol fumarate is administered to nursing women.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_85489ab0-e4ae-4479-aadb-507d1a03dd62"></a><a name="section-8.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_0ebd4c4e-605e-45ae-aee3-3f64379a3af5"></a><a name="section-8.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">ZEBETA has been used in elderly patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Response rates and mean decreases in systolic and diastolic blood pressure were similar to the decreases in younger patients in the U.S. clinical studies. Although no dose response study was conducted in elderly patients, there was a tendency for older patients to be maintained on higher doses of bisoprolol fumarate.</p>
<p>Observed reductions in heart rate were slightly greater in the elderly than in the young and tended to increase with increasing dose. In general, no disparity in adverse experience reports or dropouts for safety reasons was observed between older and younger patients. Dose adjustment based on age is not necessary.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_650b3278-05ac-4265-8e6f-f9745468676d"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Safety data are available in more than 30,000 patients or volunteers. Frequency estimates and rates of withdrawal of therapy for adverse events were derived from two U.S. placebo-controlled studies.</p>
<p>In Study A, doses of 5, 10, and 20 mg bisoprolol fumarate were administered for 4 weeks. In Study B, doses of 2.5, 10, and 40 mg of bisoprolol fumarate were administered for 12 weeks. A total of 273 patients were treated with 5-20 mg of bisoprolol fumarate; 132 received placebo.</p>
<p>Withdrawal of therapy for adverse events was 3.3% for patients receiving bisoprolol fumarate and 6.8% for patients on placebo. Withdrawals were less than 1% for either <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> or <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>/lack of energy.</p>
<p>The following table presents adverse experiences, whether or not considered drug related, reported in at least 1% of patients in these studies, for all patients studied in placebo-controlled clinical trials (2.5-40 mg), as well as for a subgroup that was treated with doses within the recommended dosage range (5-20 mg). Of the adverse events listed in the table, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> appear to be dose related.</p>
<a name="id_94c46502-dad6-4363-bc98-ef93951059bc"></a><table width="500.000">
<col width="36.2%">
<col width="19.8%">
<col width="22.0%">
<col width="22.0%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>percentage of patients with event</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top"><span class="Underline"><span class="Bold">Body System/Adverse Experience</span></span></td>
<td align="center" colspan="3" valign="top"><span class="Bold"><span class="Underline">All Adverse Experiences (%<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>)</span><br><span class="Underline">Bisoprolol Fumarate</span></span></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top"><span class="Bold">Placebo<br>(n=132)</span></td>
<td align="center" valign="top"><span class="Bold">5-20 mg<br>(n=273)</span></td>
<td align="center" valign="top"><span class="Bold">2.5-40 mg<br>(n=404)</span></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top"><span class="Underline">%</span></td>
<td align="center" valign="top"><span class="Underline">%</span></td>
<td align="center" valign="top"><span class="Underline">%</span></td>
</tr>
<tr>
<td align="left" valign="top">Skin</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">      increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></td>
<td align="center" valign="top">1.5</td>
<td align="center" valign="top">0.7</td>
<td align="center" valign="top">1.0</td>
</tr>
<tr>
<td align="left" valign="top">Musculoskeletal</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span></td>
<td align="center" valign="top">2.3</td>
<td align="center" valign="top">2.2</td>
<td align="center" valign="top">2.7</td>
</tr>
<tr>
<td align="left" valign="top">Central Nervous System</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></td>
<td align="center" valign="top">3.8</td>
<td align="center" valign="top">2.9</td>
<td align="center" valign="top">3.5</td>
</tr>
<tr>
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></td>
<td align="center" valign="top">11.4</td>
<td align="center" valign="top">8.8</td>
<td align="center" valign="top">10.9</td>
</tr>
<tr>
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoaesthesia</span></td>
<td align="center" valign="top">0.8</td>
<td align="center" valign="top">1.1</td>
<td align="center" valign="top">1.5</td>
</tr>
<tr>
<td align="left" valign="top">Autonomic Nervous System</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span></td>
<td align="center" valign="top">1.5</td>
<td align="center" valign="top">0.7</td>
<td align="center" valign="top">1.3</td>
</tr>
<tr>
<td align="left" valign="top">Heart Rate/Rhythm</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span></td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0.4</td>
<td align="center" valign="top">0.5</td>
</tr>
<tr>
<td align="left" valign="top">Psychiatric</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">vivid dreams</span></td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span></td>
<td align="center" valign="top">2.3</td>
<td align="center" valign="top">1.5</td>
<td align="center" valign="top">2.5</td>
</tr>
<tr>
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></td>
<td align="center" valign="top">0.8</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0.2</td>
</tr>
<tr>
<td align="left" valign="top">Gastrointestinal</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></td>
<td align="center" valign="top">1.5</td>
<td align="center" valign="top">2.6</td>
<td align="center" valign="top">3.5</td>
</tr>
<tr>
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></td>
<td align="center" valign="top">1.5</td>
<td align="center" valign="top">1.5</td>
<td align="center" valign="top">2.2</td>
</tr>
<tr>
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">1.1</td>
<td align="center" valign="top">1.5</td>
</tr>
<tr>
<td align="left" valign="top">Respiratory</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span></td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></td>
<td align="center" valign="top">4.5</td>
<td align="center" valign="top">2.6</td>
<td align="center" valign="top">2.5</td>
</tr>
<tr>
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></td>
<td align="center" valign="top">0.8</td>
<td align="center" valign="top">1.1</td>
<td align="center" valign="top">1.5</td>
</tr>
<tr>
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span></td>
<td align="center" valign="top">2.3</td>
<td align="center" valign="top">2.2</td>
<td align="center" valign="top">2.2</td>
</tr>
<tr>
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span></td>
<td align="center" valign="top">3.0</td>
<td align="center" valign="top">2.9</td>
<td align="center" valign="top">4.0</td>
</tr>
<tr>
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span></td>
<td align="center" valign="top">1.5</td>
<td align="center" valign="top">2.2</td>
<td align="center" valign="top">2.2</td>
</tr>
<tr>
<td align="left" valign="top">      URI</td>
<td align="center" valign="top">3.8</td>
<td align="center" valign="top">4.8</td>
<td align="center" valign="top">5.0</td>
</tr>
<tr>
<td align="left" valign="top">Body as a Whole</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span></td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">0.4</td>
<td align="center" valign="top">1.5</td>
</tr>
<tr>
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></td>
<td align="center" valign="top">0.8</td>
<td align="center" valign="top">1.1</td>
<td align="center" valign="top">1.5</td>
</tr>
<tr>
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span></td>
<td align="center" valign="top">1.5</td>
<td align="center" valign="top">6.6</td>
<td align="center" valign="top">8.2</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">      <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (peripheral)</td>
<td align="center" valign="top">3.8</td>
<td align="center" valign="top">3.7</td>
<td align="center" valign="top">3.0</td>
</tr>
</tbody>
</table>
<p>The following is a comprehensive list of adverse experiences reported with bisoprolol fumarate in worldwide studies, or in postmarketing experience (in italics):</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_423aa86a-1536-4fdd-a8b5-d0584ff27fb3"></a><a name="section-9.1"></a><p></p>
<h2>Central Nervous System </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">unsteadiness</span></span><span class="Italics">,</span> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span></span><span class="Italics">,</span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbances</span></span><span class="Italics">,</span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>/<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, decreased concentration/memory.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0a52e333-28a9-440f-bbb9-2293d87f0303"></a><a name="section-9.2"></a><p></p>
<h2>Autonomic Nervous System </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_74ba66b0-cedf-403d-bf6c-9881b205edc5"></a><a name="section-9.3"></a><p></p>
<h2>Cardiovascular </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> and other rhythm disturbances, <span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">cold extremities</span>, <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">claudication</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> on exertion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3a648cb1-f2af-4ca4-a81c-2bb1bdfbafe6"></a><a name="section-9.4"></a><p></p>
<h2>Psychiatric </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Vivid dreams</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_beead73c-d90b-40d8-8f0d-1fa2541584ee"></a><a name="section-9.5"></a><p></p>
<h2>Gastrointestinal </h2>
<p class="First">Gastric/epigastric/<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6a3ac004-3a1f-4e5b-a046-55b9a2fbade7"></a><a name="section-9.6"></a><p></p>
<h2>Musculoskeletal </h2>
<p class="First">Muscle/<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span></span><span class="Italics">,</span> back/<span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>/<span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7ca29b60-49f4-472d-ba02-b99613795be3"></a><a name="section-9.7"></a><p></p>
<h2>Skin </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span></span><span class="Italics">,</span> <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span></span><span class="Italics">,</span><span class="Italics"> <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span></span><span class="Italics">,</span><span class="Italics"> <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span></span><span class="Italics">,</span> <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_90e44464-6c35-4665-95c7-9b6966b63d96"></a><a name="section-9.8"></a><p></p>
<h2>Special Senses </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual disturbances</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span>/pressure, abnormal <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="Italics">decreased hearing</span><span class="Italics">,</span> <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span>, taste abnormalities.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9a4a4d7c-c7ca-48e9-a663-3b4445fa2601"></a><a name="section-9.9"></a><p></p>
<h2>Metabolic </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9d55586e-e775-47f5-b4a4-ca7b63b9ff51"></a><a name="section-9.10"></a><p></p>
<h2>Respiratory </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>/<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, URI.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fa1918c2-6eb6-435b-ad08-a0dad47faa9b"></a><a name="section-9.11"></a><p></p>
<h2>Genitourinary </h2>
<p class="First">Decreased libido/<span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="Italics">Peyronie’s disease</span><span class="Italics">,</span> <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="201690" conceptname="Renal colic">renal colic</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_643818ff-f7b1-43a5-8961-11ae5b76ce0e"></a><a name="section-9.12"></a><p></p>
<h2>Hematologic </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">Purpura</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f539786c-9ed9-4f6d-bd85-04f272087d76"></a><a name="section-9.13"></a><p></p>
<h2>General </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p>In addition, a variety of adverse effects have been reported with other beta-adrenergic blocking agents and should be considered potential adverse effects of ZEBETA:</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4724ba20-8665-47c1-9d10-239d56e518b9"></a><a name="section-9.14"></a><p></p>
<h2>Central Nervous System </h2>
<p class="First">Reversible mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> progressing to <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonia</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, an acute reversible syndrome characterized by <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> to time and place, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, slightly clouded sensorium.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4b47417b-4277-41ba-ad73-8740e6f8b1aa"></a><a name="section-9.15"></a><p></p>
<h2>Allergic </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, combined with aching and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_038ffee9-efad-45df-8c59-1761792acd3b"></a><a name="section-9.16"></a><p></p>
<h2>Hematologic </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_22184e69-4033-467a-8b0d-b33f3ef8d4e6"></a><a name="section-9.17"></a><p></p>
<h2>Gastrointestinal </h2>
<p class="First">Mesenteric <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5cd74eb3-dc21-42c7-afb8-3eb80f64aba6"></a><a name="section-9.18"></a><p></p>
<h2>Miscellaneous </h2>
<p class="First">The <span class="product-label-link" type="condition" conceptid="4317263" conceptname="Ocular-mucous membrane syndrome">oculomucocutaneous syndrome</span> associated with the beta-blocker practolol has not been reported with ZEBETA (bisoprolol fumarate) during investigational use or extensive foreign marketing experience.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d290de34-6359-4771-8ce8-2a8f9b55f999"></a><a name="section-9.19"></a><p></p>
<h2>LABORATORY ABNORMALITIES </h2>
<p class="First">In clinical trials, the most frequently reported laboratory change was an increase in serum triglycerides, but this was not a consistent finding.</p>
<p>Sporadic liver test abnormalities have been reported. In the U.S. controlled trials experience with bisoprolol fumarate treatment for 4-12 weeks, the incidence of concomitant elevations in <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> and SGPT from 1 to 2 times normal was 3.9%, compared to 2.5% for placebo. No patient had concomitant elevations greater than twice normal.</p>
<p>In the long-term, uncontrolled experience with bisoprolol fumarate treatment for 6-18 months, the incidence of one or more concomitant elevations in <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> and SGPT from 1 to 2 times normal was 6.2%. The incidence of multiple occurrences was 1.9%. For concomitant elevations in <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> and SGPT of greater than twice normal, the incidence was 1.5%. The incidence of multiple occurrences was 0.3%. In many cases these elevations were attributed to underlying disorders, or resolved during continued treatment with bisoprolol fumarate.</p>
<p>Other laboratory changes included small increases in uric acid, creatinine, BUN, serum potassium, glucose, and phosphorus and decreases in WBC and platelets. These were generally not of clinical importance and rarely resulted in discontinuation of bisoprolol fumarate.</p>
<p>As with other beta-blockers, ANA conversions have also been reported on bisoprolol fumarate. About 15% of patients in long-term studies converted to a positive titer, although about one-third of these patients subsequently reconverted to a negative titer while on continued therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_ff676b3f-36b9-4692-9836-122b2bfc5d12"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The most common signs expected with overdosage of a beta-blocker are <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. To date, a few cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (maximum: 2000 mg) with bisoprolol fumarate have been reported. <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> and/or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> were noted. Sympathomimetic agents were given in some cases, and all patients recovered.</p>
<p>In general, if <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occurs, ZEBETA therapy should be stopped and supportive and symptomatic treatment should be provided. Limited data suggest that bisoprolol fumarate is not dialyzable. Based on the expected pharmacologic actions and recommendations for other beta-blockers, the following general measures should be considered when clinically warranted:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4c38e86f-11c6-46e3-a863-3c585782005a"></a><a name="section-10.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></h2>
<p class="First">Administer IV atropine. If the response is inadequate, isoproterenol or another agent with positive chronotropic properties may be given cautiously. Under some circumstances, transvenous pacemaker insertion may be necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0efb3a9d-adbe-4779-b72d-d438ef74fd3f"></a><a name="section-10.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h2>
<p class="First">IV fluids and vasopressors should be administered. Intravenous glucagon may be useful.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_447040a6-e056-4b84-a23e-2470c034b3c8"></a><a name="section-10.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">Heart Block</span> (second or third degree)</h2>
<p class="First">Patients should be carefully monitored and treated with isoproterenol infusion or transvenous cardiac pacemaker insertion, as appropriate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_752fe2cc-9f79-4f98-8990-ad01e859e980"></a><a name="section-10.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span></h2>
<p class="First">Initiate conventional therapy (ie, digitalis, diuretics, inotropic agents, vasodilating agents).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_87a95bad-0b35-4941-865f-5dc0f884c186"></a><a name="section-10.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span></h2>
<p class="First">Administer bronchodilator therapy such as isoproterenol and/or aminophylline.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e29624ef-4cb9-4ce8-9e4c-51d16b7b455c"></a><a name="section-10.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<p class="First">Administer IV glucose.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_9795357f-6a11-45ed-b13a-ed2146385812"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The dose of ZEBETA must be individualized to the needs of the patient. The usual starting dose is 5 mg once daily. In some patients, 2.5 mg may be an appropriate starting dose (see Bronchospastic Disease in <a href="#i4i_warnings_id_2f7fb7b9-d290-40ee-950f-875d22708cec">WARNINGS</a>). If the antihypertensive effect of 5 mg is inadequate, the dose may be increased to 10 mg and then, if necessary, to 20 mg once daily.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a93fc8e9-974a-4a4e-b442-6257545ed25c"></a><a name="section-11.1"></a><p></p>
<h2>Patients with Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> or cirrhosis) or renal dysfunction (creatinine clearance less than 40 mL/min), the initial daily dose should be 2.5 mg and caution should be used in dose-titration. Since limited data suggest that bisoprolol fumarate is not dialyzable, drug replacement is not necessary in patients undergoing dialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0eda5183-8156-4438-b71f-9f94676ac1a9"></a><a name="section-11.2"></a><p></p>
<h2>Geriatric Patients</h2>
<p class="First">It is not necessary to adjust the dose in the elderly, unless there is also significant renal or hepatic dysfunction (see above and Geriatric Use in <a href="#i4i_precautions_id_2a6aea21-a851-4236-9972-f79abf764154">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d2b30461-de33-4703-a974-d24d03250286"></a><a name="section-11.3"></a><p></p>
<h2>Pediatric Patients</h2>
<p class="First">There is no pediatric experience with ZEBETA.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_02eb1dbc-a8aa-45db-be61-2c8f069bd8a6"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">ZEBETA<span class="Sup">®</span></span> (bisoprolol fumarate) is supplied as 5 mg and 10 mg tablets.</p>
<p>The 5 mg tablet is pink, heart-shaped, biconvex, film-coated, vertically scored in half on both sides, with an engraved stylized b/stylized b on one side and 6/0 on the reverse side, supplied as follows:</p>
<a name="id_b088180d-fa85-47df-8df9-7fed977d9cd3"></a><table width="456">
<col width="25.2%">
<col width="31.4%">
<col width="43.4%">
<tbody class="Headless"><tr class="Botrule First Last">
<td align="center" valign="top">30 </td>
<td align="left" valign="top">Unit-of-use</td>
<td align="left" valign="top">NDC 51285-060-01</td>
</tr></tbody>
</table>
<p>The 10 mg tablet is white, heart-shaped, biconvex, film-coated, with an engraved stylized b on one side and 61 on the reverse side, supplied as follows:</p>
<a name="id_1365878e-9b61-492f-baee-a00c47e2b920"></a><table width="456">
<col width="25.2%">
<col width="31.4%">
<col width="43.4%">
<tbody class="Headless"><tr class="Botrule First Last">
<td align="center" valign="top">30 </td>
<td align="left" valign="top">Unit-of-use</td>
<td align="left" valign="top">NDC 51285-061-01</td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_95db363e-608e-4f6f-b2b6-d47289f6b725"></a><a name="section-12.1"></a><p></p>
<p class="First"><span class="Bold">Store at 20<span class="Sup">o</span> to 25<span class="Sup">o</span> C (68<span class="Sup">o</span> to 77<span class="Sup">o</span>F) [See USP Controlled Room Temperature].<br>Protect from moisture.<br>Dispense in tight containers.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6bc3ba03-062e-4c81-8b24-2d17da27edbe"></a><a name="section-13"></a><p></p>
<p class="First">DURAMED PHARMACEUTICALS, INC.<br>Subsidiary of Barr Pharmaceuticals, Inc.<br>Pomona, New York 10970</p>
<p>Revised November 2010<br>BR-60, 61</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_2ea2412e-223a-43a7-9342-dced890eb744"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mg</h1>
<div class="Figure"><img alt="Zebeta 5 mg label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a11548a0-9c0f-4729-907c-75d8f99a6c85&amp;name=dffa820b-820f-4f21-a679-e7bdb047d0bc-02.jpg"></div>
<p class="First">NDC 51285-060-01</p>
<p>ZEBETA<span class="Sup">®</span><br>(bisoprolol fumarate)<br>Tablets</p>
<p>5 mg</p>
<p>30 Tablets<br>Unit-of-use</p>
<p>Rx only</p>
<p>DOSAGE: For complete directions for use, see accompanying circular.</p>
<p>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].</p>
<p>Protect from moisture.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_6bad873c-6aa2-4f6c-9337-461199f34beb"></a><a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 mg</h1>
<div class="Figure"><img alt="Zebeta 10 mg label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a11548a0-9c0f-4729-907c-75d8f99a6c85&amp;name=dffa820b-820f-4f21-a679-e7bdb047d0bc-03.jpg"></div>
<p class="First">NDC 51285-061-01</p>
<p>ZEBETA<span class="Sup">®</span><br>(bisoprolol fumarate)<br>Tablets</p>
<p>10mg</p>
<p>30 Tablets<br>Unit-of-use</p>
<p>Rx only</p>
<p>DOSAGE: For complete directions for use, see accompanying circular.</p>
<p>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].</p>
<p>Protect from moisture.</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZEBETA 		
					</strong><br><span class="contentTableReg">bisoprolol fumarate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51285-060</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BISOPROLOL FUMARATE</strong> (BISOPROLOL) </td>
<td class="formItem">BISOPROLOL FUMARATE</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS DIBASIC CALCIUM PHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">TEAR (heart shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">b;b;6;0</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51285-060-01</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019982</td>
<td class="formItem">07/31/1992</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZEBETA 		
					</strong><br><span class="contentTableReg">bisoprolol fumarate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51285-061</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BISOPROLOL FUMARATE</strong> (BISOPROLOL) </td>
<td class="formItem">BISOPROLOL FUMARATE</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS DIBASIC CALCIUM PHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">TEAR (heart shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">b;61</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51285-061-01</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019982</td>
<td class="formItem">07/31/1992</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Duramed Pharmaceuticals, Inc.
							(017038951)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 11/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>dffa820b-820f-4f21-a679-e7bdb047d0bc</div>
<div>Set id: a11548a0-9c0f-4729-907c-75d8f99a6c85</div>
<div>Version: 4</div>
<div>Effective Time: 20101116</div>
</div>
</div> <div class="DistributorName">Duramed Pharmaceuticals, Inc.</div></p>
</body></html>
